Rivia raises €13 million to modernise clinical trial data
Zurich-based startup Rivia has secured €13 million in fresh funding to expand its agentic data engine, a platform designed to streamline how sponsors, research sites and technology vendors manage data in complex clinical trials. The capital will be used to accelerate product development, strengthen engineering and data science teams, and support expansion into new therapeutic areas and geographies.
An agentic data engine for fragmented trial ecosystems
Rivia has built an agentic data engine that connects and orchestrates data flows across the fragmented infrastructure that underpins modern drug development. Today’s clinical trials typically rely on a patchwork of electronic data capture systems, eConsent tools, digital biomarkers, imaging platforms and hospital records, often spread across multiple countries and regulatory environments.
By deploying intelligent software agents that can ingest, reconcile and route data in real time, Rivia aims to reduce manual data entry, cut operational errors and shorten timelines for trial execution. The company positions its platform as a neutral data layer that can sit between sponsors, contract research organisations and site systems, while maintaining strict controls around data privacy, auditability and regulatory compliance.
Targeting the rising complexity of global studies
The new funding comes as the life sciences industry struggles with the rising complexity of decentralised trials, adaptive study designs and real-world data integration. Each additional data source adds operational risk and cost, often slowing the delivery of new therapies to patients.
Rivia says its technology can help sponsors design and run more complex protocols without overwhelming sites or patients with administrative burden. By automating data mapping and quality checks, the engine is intended to support faster interim analyses and more reliable endpoints, making it easier for companies to engage with regulators and payers.
Scaling a European health data infrastructure player
With this €13 million round, Rivia joins a growing group of European healthtech companies building infrastructure for next-generation clinical research. The startup plans to deepen integrations with existing electronic health record and trial management systems, while investing in advanced AI algorithms to further automate data curation and monitoring.
As pharmaceutical sponsors and biotechs look for ways to reduce development risk and time-to-market, platforms like Rivia’s agentic data engine are likely to become central to how complex global trials are executed.